Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Exclusivity

If you want to know more about the Exclusivity, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Exclusivity industry. More news about Exclusivity, are being released. Follow us / contact us for more Exclusivity information!
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 25 2024

    2024-11-25

    This week, there are 3 drugs in the patent and exclusivity list. They are: - ABBVIE INC's ACULAR LS, containing active ingredient KETOROLAC TROMETHAMINE - FRESENIUS KABI USA LLC's DIPRIVAN, containing active ingredient PROPOFOL - GLOBAL BLOOD THERAPEUTICS INC's OXBRYTA, containing active ingredient VOXELOTOR Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 18 2024

    2024-11-18

    This week, there are 8 drugs in the patent and exclusivity list. They are: - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE - NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE - BRISTOL MYERS SQUIBB's REVLIMID, containing active ingredient LENALIDOMIDE - CUMBERLAND PHARMACEUTICALS INC's CALDOLOR, containing active ingredient IBUPROFEN - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ALNYLAM PHARMACEUTICALS INC's GIVLAARI, containing active ingredient GIVOSIRAN SODIUM - AADI BIOSCIENCE INC's FYARRO, containing active ingredient SIROLIMUS Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 11 2024

    2024-11-11

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - KYOWA KIRIN INC's NOURIANZ, containing active ingredient ISTRADEFYLLINE - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - VANDA PHARMACEUTICALS INC's PONVORY, containing active ingredient PONESIMOD - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - BIOMARIN PHARMACEUTICAL INC's KUVAN, containing active ingredient SAPROPTERIN DIHYDROCHLORIDE - PROVENSIS LTD's VARITHENA, containing active ingredient POLIDOCANOL - BEIGENE USA INC's BRUKINSA, containing active ingredient ZANUBRUTINIB - SHIONOGI INC's FETROJA, containing active ingredient CEFIDEROCOL SULFATE TOSYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 4 2024

    2024-11-04

    This week, there are 11 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's XIIDRA, containing active ingredient LIFITEGRAST - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - MYLAN SPECIALTY LP's TOBI PODHALER, containing active ingredient TOBRAMYCIN - ASTRAZENECA LP's SYMBICORT, containing active ingredient BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - ASTRAZENECA AB's BYETTA, containing active ingredient EXENATIDE SYNTHETIC - HOFFMANN-LA ROCHE INC's ALECENSA, containing active ingredient ALECTINIB HYDROCHLORIDE - HOFFMANN LA ROCHE INC's ZELBORAF, containing active ingredient VEMURAFENIB - GISKIT PHARMA BV's EXEM FOAM KIT, containing active ingredient AIR POLYMER-TYPE A - MERCK SHARP AND DOHME CORP's PREVYMIS, containing active ingredient LETERMOVIR - MERCK SHARP AND DOHME LLC's PREVYMIS, containing active ingredient LETERMOVIR - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Oct 28 2024

    2024-10-28

    This week, there are 6 drugs in the patent and exclusivity list. They are: - ALEXZA PHARMACEUTICALS INC's ADASUVE, containing active ingredient LOXAPINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - CORMEDIX INC's DEFENCATH, containing active ingredient HEPARIN SODIUM; TAUROLIDINE - ABBVIE INC's VUITY, containing active ingredient PILOCARPINE HYDROCHLORIDE - SANOFI AVENTIS US LLC's AUBAGIO, containing active ingredient TERIFLUNOMIDE - ASTRAZENECA UK LTD's CALQUENCE, containing active ingredient ACALABRUTINIB Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Oct 21 2024

    2024-10-22

    This week, there are 3 drugs in the patent and exclusivity list. They are: - BRISTOL-MYERS SQUIBB CO's ABRAXANE, containing active ingredient PACLITAXEL - VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - BAUSCH AND LOMB INC's XIPERE, containing active ingredient TRIAMCINOLONE ACETONIDE Read More
  • Total 4 pages  Go to Page
  • Go